That’s exactly right—Bayer has come full circle from being a producer of plasma-derived proteins to a proponent of recombinant plasma proteins. They have inked major deals for alfimeprase (recombinant fibrolase analogue) and recombinant thrombin. (Alfimeprase hasn’t worked out, but that’s another story.)
Your comment about Pharming’s rhFibrinogen is apropos to the quiz in #msg-20587893
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”